NBIX position history
The shares of Neurocrine Biosciences (NBIX) that DAFNA Capital Management LLC reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2021 Q3: 84,655 shares, $8.1M, 2.2% of portfolio
- 2021 Q4: 83,655 shares, $7.1M, 1.8% of portfolio, Reduce −1.2%
- 2022 Q1: 83,655 shares, $7.8M, 2.0% of portfolio
- 2022 Q2: 82,655 shares, $8.1M, 2.2% of portfolio, Reduce −1.2%
- 2022 Q3: 80,155 shares, $8.5M, 2.3% of portfolio, Reduce −3.0%
- 2022 Q4: 73,121 shares, $8.7M, 2.5% of portfolio, Reduce −8.8%
- 2023 Q1: 74,615 shares, $7.6M, 2.3% of portfolio, Add +2.0%
- 2023 Q2: 74,615 shares, $7M, 1.9% of portfolio
- 2023 Q3: 73,615 shares, $8.3M, 2.6% of portfolio, Reduce −1.3%
- 2023 Q4: 72,615 shares, $9.6M, 2.3% of portfolio, Reduce −1.4%
- 2024 Q1: 71,615 shares, $9.9M, 2.2% of portfolio, Reduce −1.4%
- 2024 Q2: 71,615 shares, $9.9M, 2.4% of portfolio
- 2024 Q3: 69,615 shares, $8M, 1.9% of portfolio, Reduce −2.8%
- 2024 Q4: 71,615 shares, $9.8M, 2.5% of portfolio, Add +2.9%
- 2025 Q1: 71,615 shares, $7.9M, 2.2% of portfolio
- 2025 Q2: 70,615 shares, $8.9M, 2.5% of portfolio, Reduce −1.4%
- 2025 Q3: 70,615 shares, $9.9M, 2.4% of portfolio
- 2025 Q4: 70,615 shares, $10M, 2.3% of portfolio
- 2026 Q1: 70,615 shares, $9.3M, 2.1% of portfolio
- 2026 Q2: 57,769 shares, $9.7M, 1.9% of portfolio, Reduce −18.2%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|